Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001104659-25-081913
Filing Date
2025-08-22
Accepted
2025-08-22 16:31:10
Documents
4

Document Format Files

Seq Description Document Type Size
1 424B5 tm2523989d1_424b5.htm 424B5 338820
2 GRAPHIC tm2523989d1_424b5img001.jpg GRAPHIC 6215
3 GRAPHIC tm2523989d1_424b5img003.jpg GRAPHIC 6625
4 GRAPHIC tm2523989d1_424b5img002.jpg GRAPHIC 9294
  Complete submission text file 0001104659-25-081913.txt   371052
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-286802 | Film No.: 251246695
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)